Article
Cell cycle-coupled expansion of AR activity promotes cancer progression.
Oncogene - 23 Mar 2017
McNair C, Urbanucci A, Comstock C E S, Augello M A, Goodwin J F, Launchbury R, Zhao S G, Schiewer M J, Ertel A, Karnes J, Davicioni E, Wang L, Wang Q, Mills I G, Feng F Y, Li W, Carroll J S, Knudsen K E
Abstract excerpt
The androgen receptor (AR) is required for prostate cancer (PCa) survival and progression, and ablation of AR activity is the first line of therapeutic intervention for disseminated disease. While initially effective, recurrent tumors ultimately arise for which there is no durable cure. Despite the dependence of PCa on AR activity throughout the course of disease, delineation of the AR-dependent transcriptional...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.